Apollo Hospitals Brings Next-Generation Lysin Science to India's Fight Against AMR - Collaborates with Precisio Biotix
Apollo Hospitals has partnered with Precisio Biotix to develop and clinically validate lysin-based antimicrobials in India. This collaboration aims to address antimicrobial resistance (AMR) by using enzyme-based therapies that target specific pathogens without the resistance issues associated with traditional antibiotics.
HYDERABAD, India , July 21, 2026 /PRNewswire/ -- Apollo Hospitals today announced a strategic collaboration with Precisio Biotix to accelerate the development and clinical adoption of lysin-based antimicrobials in India - marking a significant step forward in combating antimicrobial resistance (AMR). This partnership will focus on translational research, clinical validation, and potential deployment pathways for lysin-based therapies across Apollo's network, with a focus on infectious diseases where existing treatment options are limited.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in